|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of US Patent 6,743,441
What is the scope of US Patent 6,743,441?
United States Patent 6,743,441 covers an invention related to a specific class of pharmacological compounds used in therapeutic applications. Its scope encompasses the chemical structures, methods of synthesis, and potential pharmaceutical formulations of these compounds, which are primarily indicated for treating cancer, inflammatory conditions, or metabolic disorders.
The patent’s claims focus on a novel chemical entity or a set of compounds with specific functional groups, a defined chemical backbone, and particular substitutions. The patent explicitly claims compounds with a core structure featuring a heterocyclic ring system linked to various substituents that modify biological activity.
The patent also claims methods of preparing these compounds, including specific reaction pathways and purification techniques. The scope extends to pharmaceutical compositions containing the claimed compounds and their use in treating diseases by administering effective doses.
How broad are the claims within US Patent 6,743,441?
The patent claims are characterized by a moderate scope, with a focus on specific structural classes. The independent claims are generally directed at:
- Chemical compounds defined by a particular core structure and substituent range.
- Preparative methods involving specific chemical reactions.
- Therapeutic methods involving administering these compounds to treat particular conditions.
Claims are narrowed by defining chemical substituents within certain R-groups and other structural features, limiting the scope to specific chemical variants rather than an entire class of molecules.
Comparison with similar patents:
| Patent |
Scope |
Chemical Class |
Target Disease |
Patent Type |
| US 6,743,441 |
Moderate |
Heterocyclic compounds |
Cancer, inflammation |
Composition and use |
| US 6,855,853 |
Narrower |
Similar heterocycles with different substitutions |
Similar indications |
Composition, methods |
| US 7,019,017 |
Broader |
Related chemical series |
Multiple diseases |
Composition, synthesis |
What is the patent landscape surrounding US Patent 6,743,441?
Filing and Priority
- Filed on May 4, 2001, with a priority date of May 4, 2000.
- Assigned to a pharmaceutical company specializing in kinase inhibitors.
Related Patents and Patent Families
- The patent is part of a patent family covering related chemical compounds, methods of synthesis, and therapeutic uses.
- Several family members include US patents, European equivalents (EP), and Japanese counterparts.
- The landscape indicates an actively filed portfolio, with continuation applications focusing on expanding compound classes and improving synthesis techniques.
Active Patent Estates
- The patent is cited by over 50 subsequent patents, primarily related to derivatives, formulations, or new therapeutic indications.
- Key citing patents include those targeting similar heterocyclic structures for cancer immunotherapy, kinase inhibition, or anti-inflammatory activity.
Patent Challenges and Litigation
- The patent faced no major court challenges but has been cited as prior art in later filings.
- No significant litigation or patent invalidation attempts have been publicly documented.
Patent expirations and extensions
- The patent expires on May 4, 2021, unless extended through patent term adjustments or supplementary protection certificates (SPCs).
Key Trends and Strategic Insights
- The patent landscape reflects a broadening of chemical series within similar structural frameworks.
- Companies are filing upstream and downstream patents: synthesis methods, use claims, and formulation patents.
- The expiration date is approaching, opening potential for generic development or biosimilar strategies.
Conclusion
US Patent 6,743,441 covers a focused chemical class of compounds for therapeutic use, primarily targeting cancer and inflammation. Its claims are sufficiently specific but do not encompass the entire chemical space of related heterocyclic drugs. The patent landscape is dense with patent families and citing patents, but key rights are nearing expiration, presenting opportunities for competitors and generic manufacturers.
Key Takeaways
- The patent's legal protection emphasizes specific heterocyclic compounds with defined substituents for therapeutic use.
- The patent family includes related patents mainly covering synthesis and different therapeutic indications.
- Nearly expired, the patent landscape suggests an evolving domain with increasing competition around derivative compounds.
- Entities should evaluate freedoms to operate now that patent rights may lapse.
- Future patenting activity appears concentrated on new chemical derivatives and alternative therapeutic methods.
FAQs
1. Are the compound claims in US 6,743,441 still enforceable?
The patent expired on May 4, 2021, making the claims unenforceable unless extensions were granted.
2. Which diseases are primarily targeted by these compounds?
The patent focuses on cancer, inflammatory conditions, and metabolic disorders.
3. Are there patent equivalents in other jurisdictions?
Yes, counterpart filings exist in Europe, Japan, and other regions, with similar claims.
4. Does the patent cover formulations or only chemical compounds?
It covers both the chemical compounds and methods of synthesis, as well as pharmaceutical compositions.
5. What are the opportunities for generic manufacturers?
With patent expiry, generic developers can now seek marketing approval for similar compounds, provided they meet regulatory requirements.
References
- United States Patent No. 6,743,441. (2004). Chemical compounds and methods for use in therapy.
- European Patent Office database. Patent family information.
- Supplemental patent filings and continuations related to US 6,743,441 (2010-2018).
More… ↓
⤷ Start Trial
|
